Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Loïc LebellecFrançois BertucciEmmanuelle Tresch-BruneelIsabelle Ray-CoquardAxel Le CesneEmmanuelle BompasJean-Yves BlayAntoine ItalianoOlivier MirThomas RyckewaertYves ToironLuc CamoinAnthony GoncalvesNicolas PenelMarie-Cécile Le DeleyPublished in: BMC cancer (2018)
Retrospectively registered on EudraCT N° 2009-017020-59 and NCT01303497 (February 24, 2011).
Keyphrases